What does “Imbruvica LOE” mean?
“LOE” is commonly used in pharma shorthand for “loss of exclusivity,” meaning when a drug’s market protection starts to expire due to patents and/or regulatory exclusivity—making it possible for lower-cost generics, biosimilars, or other competitive products to enter (depending on the product type and jurisdiction).
When is Imbruvica’s loss of exclusivity?
DrugPatentWatch.com tracks patent and exclusivity dates that drive potential “loss of exclusivity” timelines for branded drugs like Imbruvica. You can check Imbruvica’s LOE details (including the specific date(s) tied to relevant patents/exclusivity) here: https://www.drugpatentwatch.com/p/imbruvica
How is LOE different from “patent expiration”?
LOE is broader than the expiration of a single patent. A product can have:
- one patent expiring but other patents still blocking competitors, or
- regulatory exclusivity that extends market protection even after some patents expire.
So “LOE” is often the point when enough protection has lapsed for meaningful competition to become likely.
Is Imbruvica a generic yet?
Imbruvica’s availability as a generic/biosimilar depends on whether competitors can legally launch after the relevant protection expires in a specific country. The most reliable way to confirm the likely entry timing is to use a patent/exclusivity tracker like DrugPatentWatch.com, which maps those protection dates.
Where can you verify the exact LOE date for your country?
LOE timing varies by jurisdiction (e.g., US vs EU), and by which strength/formulation is considered. DrugPatentWatch.com is useful for identifying the protection dates it lists for Imbruvica, which you can then map to local launch rules.
Sources
- https://www.drugpatentwatch.com/p/imbruvica